Efficacy and Safety of Calculus Bovis Sativus (CBS) for Intracerebral Hemorrhage(CBSinICH)
NCT ID: NCT07080632
Last Updated: 2025-10-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
300 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-10-01
Study Completion Date
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The most common cause of death for Chinese patients is intracerebral hemorrhage(ICH), particularly cerebral infarction. It places a heavy burden on people, families, and society as a whole and poses considerable risks of death and disability. The disease is difficult to identify, and is frequently detected only after it progresses to the point of vascular cognitive dysfunction. The primary ischemia necrosis of brain nerve cells and the activation of inflammatory cells are their pathologic processes.
According to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being, and stimulate alertness. Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products. It has received approval from the China Food and Drug Administration for the essential treatment of comatose patients. CBS consists of three primary constituents: bilirubin, bile acids, and taurine. Scientific evidence has demonstrated that all of these components possess anti-inflammatory, antioxidant, and neuroprotective properties.
The investigators' objective is to carry out an investigator-initiated clinical study to assess the efficacy of orally administered CBS in treating intracerebral hemorrhag diseases in humans.
According to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being, and stimulate alertness. Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products. It has received approval from the China Food and Drug Administration for the essential treatment of comatose patients. CBS consists of three primary constituents: bilirubin, bile acids, and taurine. Scientific evidence has demonstrated that all of these components possess anti-inflammatory, antioxidant, and neuroprotective properties.
The investigators' objective is to carry out an investigator-initiated clinical study to assess the efficacy of orally administered CBS in treating intracerebral hemorrhag diseases in humans.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
NCT06474507
Ischemic Cerebrovascular Disease
Acute Ischemic Stroke
Cerebral Small Vessel Diseases
RECRUITING
NA
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
NCT06474520
Idiopathic Inflammatory Demyelinating Disease
Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorder
+2 more
RECRUITING
NA
Bovis Calculus Stativus Treat Acute Cerebral Ischemic Stroke With Impaired Consciousness
NCT07240467
Acute Ischemic Stroke AIS
Impaired Consciousness
NOT_YET_RECRUITING
PHASE2/PHASE3
A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
NCT06255977
Intracerebral Hemorrhage
RECRUITING
PHASE2
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
NCT03271697
Aneurysmal Subarachnoid Hemorrhage
UNKNOWN
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Intracerebral Hemorrhage
Brain Hemorrhage
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBS therapy, CBS dosage: 300mg per day from day 1 to day 7, in ICH cohort
Subjects in ICH cohort of this arm will receive general therapy plus CBS.
Group Type
EXPERIMENTAL
Calculus bovis sativus (CBS)
Intervention Type
DRUG
Subjects will orally receive 300mg CBS per day from day 1 to day 7
NCB therapy,NCB dosage: 300mg per day from day 1 to day 7, in ICH cohort
Subjects in ICH cohort of this arm will receive general therapy plus NCB.
Group Type
EXPERIMENTAL
Natural Calculus Bovis(NCB)
Intervention Type
DRUG
Subjects will orally receive 300mg NCB per day from day 1 to day 7
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calculus bovis sativus (CBS)
Subjects will orally receive 300mg CBS per day from day 1 to day 7
Intervention Type
DRUG
Natural Calculus Bovis(NCB)
Subjects will orally receive 300mg NCB per day from day 1 to day 7
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject and/or their legal guardian(s) must have full legal capacity, fully understand the purpose, significance, methodology, potential risks, possible adverse effects, types of personal data collected, scope of use, processing methods, retention period, and other relevant information regarding this study. Consent must be given voluntarily.This study will strictly comply with the Personal Information Protection Law, Data Security Law, and other applicable laws/regulations, implementing necessary measures to ensure data security and prevent leakage, tampering, or loss.Upon consent, subjects/guardians authorize the research institution to lawfully process relevant health data, including but not limited to storage, analysis, and statistical use.The institution will strictly limit the scope of personal data usage; no additional purposes will be pursued without separate consent.Subjects/guardians retain the right to access, copy, correct, or delete their data, withdraw consent, or request explanations from the institution.All personal data processing will adhere to legal requirements, ensuring legitimacy, justification, and necessity.
2. Male or female, aged 18-80 years (inclusive) at the time of providing informed nsent.
3. All sexually active participants (male and female of reproductive potential) must use effective contraception during the study and for at least 6 months after the last dose of the investigational treatment.Participants must not donate sperm or eggs during the study or for 6 months post-treatment.
4. Confirmed diagnosis meeting the following criteria:
1. Hypertensive ICH per Diagnostic Criteria for Spontaneous Intracerebral Hemorrhage in Adults , verified by cranial CT.
2. Traditional Chinese Medicine (TCM) diagnostic criteria (per Stroke Diagnosis and Efficacy Evaluation Standards by the National TCM Administration's Emergency Research Collaboration Group for Encephalopathy):Primary symptoms: Hemiplegia, impaired consciousness, slurred speech/mutism, sensory deficits, facial deviation.Secondary symptoms: Headache, dizziness, pupillary changes, dysphagia, gaze palsy, ataxia.Diagnosis: ≥2 primary symptoms or 1 primary + 2 secondary symptoms, combined with onset context, predisposing factors, prodromal signs, and age. Imaging may substitute for clinical criteria if insufficient.
3. Hemorrhage volume: 5-10 mL.
4. Clinical presentation: Impaired consciousness or significant neurological deficits.
5. Exclusion: No respiratory failure.
5. Neurological examinations must demonstrate stability within 30 days prior to baseline (Visit 1).
2. Male or female, aged 18-80 years (inclusive) at the time of providing informed nsent.
3. All sexually active participants (male and female of reproductive potential) must use effective contraception during the study and for at least 6 months after the last dose of the investigational treatment.Participants must not donate sperm or eggs during the study or for 6 months post-treatment.
4. Confirmed diagnosis meeting the following criteria:
1. Hypertensive ICH per Diagnostic Criteria for Spontaneous Intracerebral Hemorrhage in Adults , verified by cranial CT.
2. Traditional Chinese Medicine (TCM) diagnostic criteria (per Stroke Diagnosis and Efficacy Evaluation Standards by the National TCM Administration's Emergency Research Collaboration Group for Encephalopathy):Primary symptoms: Hemiplegia, impaired consciousness, slurred speech/mutism, sensory deficits, facial deviation.Secondary symptoms: Headache, dizziness, pupillary changes, dysphagia, gaze palsy, ataxia.Diagnosis: ≥2 primary symptoms or 1 primary + 2 secondary symptoms, combined with onset context, predisposing factors, prodromal signs, and age. Imaging may substitute for clinical criteria if insufficient.
3. Hemorrhage volume: 5-10 mL.
4. Clinical presentation: Impaired consciousness or significant neurological deficits.
5. Exclusion: No respiratory failure.
5. Neurological examinations must demonstrate stability within 30 days prior to baseline (Visit 1).
Exclusion Criteria
1. Medical History and Current Health Status
1. Any clinically significant history of cardiac, endocrine, hematologic, hepatic, immune, infectious, metabolic, renal, pulmonary, neurological, dermatologic, psychiatric, or other major diseases, as determined by the investigator, that would interfere with trial participation.
2. Presence of any untreated intracranial tumor at baseline (randomization).
3. Alternative causes of symptoms, including:Cerebral hemorrhage due to hematologic disorders or bleeding diathesis.Subarachnoid hemorrhage secondary to trauma.Vascular abnormalities (e.g., aneurysms, arteriovenous malformations).Traumatic brain injury, CNS infections, septic encephalopathy, metabolic encephalopathy, epileptic disorders, mitochondrial diseases, Klein-Levin syndrome, Creutzfeldt-Jakob disease, rheumatologic disorders, Reyes syndrome, or inborn metabolic errors.
4. Any major surgery within 4 weeks before baseline, excluding:
Laparoscopic or minor procedures (defined as those requiring only local anesthesia/conscious sedation, performed outpatient; e.g., toenail surgery, mole excision, wisdom tooth extraction).Exclusion: Thymoma or teratoma resection.
5. Planned surgery during the study (except minor procedures).
6. History of severe allergies/anaphylaxis or any hypersensitivity reaction that may be exacerbated by study treatment components.
7. Current or history of malignancy (including solid tumors and hematologic malignancies), except:Basal cell/squamous cell carcinoma fully excised and cured ≥12 months before screening.Subjects with cancer in remission for \>5 years may be included after sponsor approval.
8. History of gastrointestinal surgery (except appendectomy/cholecystectomy \>6 months before screening), irritable bowel syndrome, inflammatory bowel disease (Crohn's, ulcerative colitis), or other clinically significant active GI disorders.
9. Clinically significant recurrent/active GI symptoms (e.g., nausea, diarrhea, dyspepsia, constipation) within 90 days before screening, requiring:
New symptomatic treatment (e.g., GERD medication initiation) or dose adjustments within 90 days.
10. History of diverticulitis or severe GI abnormalities (e.g., symptomatic diverticulosis) that may increase risks (e.g., perforation).
11. Blood/plasma/platelet donation (≥1 unit) within 90 days before screening.
12. Active suicidal ideation within 6 months or suicide attempt within 3 years before screening.
13. Clinically significant laboratory abnormalities per investigator judgment.
14. Pregnancy, lactation, or plans to conceive during the study or within 3 months post-treatment.
Women of childbearing potential must have negative serum/urine pregnancy tests at screening and pre-dose.
15. Physical/mental conditions compromising safety or efficacy assessments.
16. Screening/baseline systolic BP \>150 mmHg or \<90 mmHg after 5-minute rest (one repeat allowed; exclusion if persistent).
17. Within 3 months before screening:Second-/third-degree AV block, sick sinus syndrome, uncontrolled atrial fibrillation, severe/unstable angina, congestive heart failure, myocardial infarction, or major ECG abnormalities (QTc \>450 ms \[men\] or \>470 ms \[women; Fridericia correction\]).
18. Planned elective procedures/surgery after ICF signing.
19. Conditions impairing drug absorption (e.g., gastrectomy).
20. History of heparin allergy or heparin-induced thrombocytopenia.
21. Clinically relevant abnormalities in medical history, physical exam, ECG, or lab tests.
2. Infection Risk
1. HIV infection (positive test/history).
2. Active hepatitis C (HCV Ab+ with detectable HCV RNA).Allowed: HCV Ab+ with undetectable RNA.
3. Active hepatitis B (HBsAg+ and/or anti-HBc+).Allowed: Prior natural infection (HBsAg-/anti-HBc+/anti-HBs+) or vaccination (HBsAg-/anti-HBc-/anti-HBs+).
4. Chronic/severe/recurrent infections (e.g., pneumonia, sepsis) within 90 days before baseline.
5. TB diagnosis/latent TB (positive IGRA or 2 consecutive tests).
6. Bacterial/fungal/viral infection symptoms (including URI) within 28 days before baseline Re-screening permitted after successful treatment of localized fungal infections (e.g., candidiasis, tinea).
7. Infection requiring hospitalization/IV antibiotics within 4 weeks before baseline.
8. Live/attenuated vaccination within 28 days before baseline or planned during the study.
9. Contraindications to rescue therapies (rituximab, IVIG, high-dose corticosteroids, IV cyclophosphamide).
10. Prior treatments:Total lymphoid irradiation, cladribine, T-cell/TCR vaccines, stem cell transplant (any time).
3. Laboratory Values
1. Clinically significant abnormal lab results at screening/baseline (investigator discretion).
2. Hematologic abnormalities at screening:
* WBC \<3.0 × 10³/µL
* ANC \<2.0 × 10³/µL
* Lymphocytes \<0.5 × 10³/µL
* Platelets \<100 × 10³/µL
* ALT/AST/GGT ≥3× ULN or bilirubin \>2× ULN
* eGFR ≤60 mL/min/1.73 m²
* Lymphocytes \<LLN
3. Urinalysis abnormalities at screening:
* β-2-microglobulin \>0.3 μg/mL
* Albumin/creatinine ratio \>22.6 mg/mmol
4. Other
1. Prior participation in this study.
2. Blood donation (≥1 unit) within 90 days, plasma within 1 week, or platelets within 6 weeks before screening.
3. Alcohol/drug abuse within the past year (investigator-determined).
4. Pregnancy, lactation, or plans to conceive/breastfeed during the study or within 30 days post-treatment.
5. Current or prior (within 90 days) participation in another clinical trial.
6. Clinically significant suicidal ideation/behavior within 12 months (per C-SSRS).
7. Inability/unwillingness to comply with protocol requirements.
8. Severe hearing/visual impairment, language barriers, claustrophobia, or other conditions preventing neuropsychological assessments/MRI.
9. Any other reason deemed by the investigator/sponsor to preclude enrollment.
1. Any clinically significant history of cardiac, endocrine, hematologic, hepatic, immune, infectious, metabolic, renal, pulmonary, neurological, dermatologic, psychiatric, or other major diseases, as determined by the investigator, that would interfere with trial participation.
2. Presence of any untreated intracranial tumor at baseline (randomization).
3. Alternative causes of symptoms, including:Cerebral hemorrhage due to hematologic disorders or bleeding diathesis.Subarachnoid hemorrhage secondary to trauma.Vascular abnormalities (e.g., aneurysms, arteriovenous malformations).Traumatic brain injury, CNS infections, septic encephalopathy, metabolic encephalopathy, epileptic disorders, mitochondrial diseases, Klein-Levin syndrome, Creutzfeldt-Jakob disease, rheumatologic disorders, Reyes syndrome, or inborn metabolic errors.
4. Any major surgery within 4 weeks before baseline, excluding:
Laparoscopic or minor procedures (defined as those requiring only local anesthesia/conscious sedation, performed outpatient; e.g., toenail surgery, mole excision, wisdom tooth extraction).Exclusion: Thymoma or teratoma resection.
5. Planned surgery during the study (except minor procedures).
6. History of severe allergies/anaphylaxis or any hypersensitivity reaction that may be exacerbated by study treatment components.
7. Current or history of malignancy (including solid tumors and hematologic malignancies), except:Basal cell/squamous cell carcinoma fully excised and cured ≥12 months before screening.Subjects with cancer in remission for \>5 years may be included after sponsor approval.
8. History of gastrointestinal surgery (except appendectomy/cholecystectomy \>6 months before screening), irritable bowel syndrome, inflammatory bowel disease (Crohn's, ulcerative colitis), or other clinically significant active GI disorders.
9. Clinically significant recurrent/active GI symptoms (e.g., nausea, diarrhea, dyspepsia, constipation) within 90 days before screening, requiring:
New symptomatic treatment (e.g., GERD medication initiation) or dose adjustments within 90 days.
10. History of diverticulitis or severe GI abnormalities (e.g., symptomatic diverticulosis) that may increase risks (e.g., perforation).
11. Blood/plasma/platelet donation (≥1 unit) within 90 days before screening.
12. Active suicidal ideation within 6 months or suicide attempt within 3 years before screening.
13. Clinically significant laboratory abnormalities per investigator judgment.
14. Pregnancy, lactation, or plans to conceive during the study or within 3 months post-treatment.
Women of childbearing potential must have negative serum/urine pregnancy tests at screening and pre-dose.
15. Physical/mental conditions compromising safety or efficacy assessments.
16. Screening/baseline systolic BP \>150 mmHg or \<90 mmHg after 5-minute rest (one repeat allowed; exclusion if persistent).
17. Within 3 months before screening:Second-/third-degree AV block, sick sinus syndrome, uncontrolled atrial fibrillation, severe/unstable angina, congestive heart failure, myocardial infarction, or major ECG abnormalities (QTc \>450 ms \[men\] or \>470 ms \[women; Fridericia correction\]).
18. Planned elective procedures/surgery after ICF signing.
19. Conditions impairing drug absorption (e.g., gastrectomy).
20. History of heparin allergy or heparin-induced thrombocytopenia.
21. Clinically relevant abnormalities in medical history, physical exam, ECG, or lab tests.
2. Infection Risk
1. HIV infection (positive test/history).
2. Active hepatitis C (HCV Ab+ with detectable HCV RNA).Allowed: HCV Ab+ with undetectable RNA.
3. Active hepatitis B (HBsAg+ and/or anti-HBc+).Allowed: Prior natural infection (HBsAg-/anti-HBc+/anti-HBs+) or vaccination (HBsAg-/anti-HBc-/anti-HBs+).
4. Chronic/severe/recurrent infections (e.g., pneumonia, sepsis) within 90 days before baseline.
5. TB diagnosis/latent TB (positive IGRA or 2 consecutive tests).
6. Bacterial/fungal/viral infection symptoms (including URI) within 28 days before baseline Re-screening permitted after successful treatment of localized fungal infections (e.g., candidiasis, tinea).
7. Infection requiring hospitalization/IV antibiotics within 4 weeks before baseline.
8. Live/attenuated vaccination within 28 days before baseline or planned during the study.
9. Contraindications to rescue therapies (rituximab, IVIG, high-dose corticosteroids, IV cyclophosphamide).
10. Prior treatments:Total lymphoid irradiation, cladribine, T-cell/TCR vaccines, stem cell transplant (any time).
3. Laboratory Values
1. Clinically significant abnormal lab results at screening/baseline (investigator discretion).
2. Hematologic abnormalities at screening:
* WBC \<3.0 × 10³/µL
* ANC \<2.0 × 10³/µL
* Lymphocytes \<0.5 × 10³/µL
* Platelets \<100 × 10³/µL
* ALT/AST/GGT ≥3× ULN or bilirubin \>2× ULN
* eGFR ≤60 mL/min/1.73 m²
* Lymphocytes \<LLN
3. Urinalysis abnormalities at screening:
* β-2-microglobulin \>0.3 μg/mL
* Albumin/creatinine ratio \>22.6 mg/mmol
4. Other
1. Prior participation in this study.
2. Blood donation (≥1 unit) within 90 days, plasma within 1 week, or platelets within 6 weeks before screening.
3. Alcohol/drug abuse within the past year (investigator-determined).
4. Pregnancy, lactation, or plans to conceive/breastfeed during the study or within 30 days post-treatment.
5. Current or prior (within 90 days) participation in another clinical trial.
6. Clinically significant suicidal ideation/behavior within 12 months (per C-SSRS).
7. Inability/unwillingness to comply with protocol requirements.
8. Severe hearing/visual impairment, language barriers, claustrophobia, or other conditions preventing neuropsychological assessments/MRI.
9. Any other reason deemed by the investigator/sponsor to preclude enrollment.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jianmin Pharmaceutical Group Co., LTD.
INDUSTRY
Sponsor Role
collaborator
Tongji Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Wang
Professor of Neurology, President of Tongji Hospital
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430000
Hubei, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang F, Deng Y, Wang H, Fu J, Wu G, Duan Z, Zhang X, Cai Y, Zhou H, Yin J, He Y. Gut microbiota-mediated ursodeoxycholic acids regulate the inflammation of microglia through TGR5 signaling after MCAO. Brain Behav Immun. 2024 Jan;115:667-679. doi: 10.1016/j.bbi.2023.11.021. Epub 2023 Nov 19.
Reference Type
BACKGROUND
Martinez-Vacas A, Di Pierdomenico J, Gallego-Ortega A, Valiente-Soriano FJ, Vidal-Sanz M, Picaud S, Villegas-Perez MP, Garcia-Ayuso D. Systemic taurine treatment affords functional and morphological neuroprotection of photoreceptors and restores retinal pigment epithelium function in RCS rats. Redox Biol. 2022 Nov;57:102506. doi: 10.1016/j.redox.2022.102506. Epub 2022 Oct 14.
Reference Type
BACKGROUND
Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2019 May;90(5):529-536. doi: 10.1136/jnnp-2018-317964. Epub 2018 Apr 17.
Reference Type
BACKGROUND
Liu K, Zhu R, Jiang H, Li B, Geng Q, Li Y, Qi J. Taurine inhibits KDM3a production and microglia activation in lipopolysaccharide-treated mice and BV-2 cells. Mol Cell Neurosci. 2022 Sep;122:103759. doi: 10.1016/j.mcn.2022.103759. Epub 2022 Jul 25.
Reference Type
BACKGROUND
Jangra A, Gola P, Singh J, Gond P, Ghosh S, Rachamalla M, Dey A, Iqbal D, Kamal M, Sachdeva P, Jha SK, Ojha S, Kumar D, Jha NK, Chopra H, Tan SC. Emergence of taurine as a therapeutic agent for neurological disorders. Neural Regen Res. 2024 Jan;19(1):62-68. doi: 10.4103/1673-5374.374139.
Reference Type
BACKGROUND
Hurley MJ, Bates R, Macnaughtan J, Schapira AHV. Bile acids and neurological disease. Pharmacol Ther. 2022 Dec;240:108311. doi: 10.1016/j.pharmthera.2022.108311. Epub 2022 Nov 16.
Reference Type
BACKGROUND
Khalaf K, Tornese P, Cocco A, Albanese A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener. 2022 Jun 4;11(1):33. doi: 10.1186/s40035-022-00307-z.
Reference Type
BACKGROUND
Li CX, Wang XQ, Cheng FF, Yan X, Luo J, Wang QG. Hyodeoxycholic acid protects the neurovascular unit against oxygen-glucose deprivation and reoxygenation-induced injury in vitro. Neural Regen Res. 2019 Nov;14(11):1941-1949. doi: 10.4103/1673-5374.259617.
Reference Type
BACKGROUND
Bhargava P, Smith MD, Mische L, Harrington E, Fitzgerald KC, Martin K, Kim S, Reyes AA, Gonzalez-Cardona J, Volsko C, Tripathi A, Singh S, Varanasi K, Lord HN, Meyers K, Taylor M, Gharagozloo M, Sotirchos ES, Nourbakhsh B, Dutta R, Mowry EM, Waubant E, Calabresi PA. Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. J Clin Invest. 2020 Jul 1;130(7):3467-3482. doi: 10.1172/JCI129401.
Reference Type
BACKGROUND
Liu HW, Gong LN, Lai K, Yu XF, Liu ZQ, Li MX, Yin XL, Liang M, Shi HS, Jiang LH, Yang W, Shi HB, Wang LY, Yin SK. Bilirubin gates the TRPM2 channel as a direct agonist to exacerbate ischemic brain damage. Neuron. 2023 May 17;111(10):1609-1625.e6. doi: 10.1016/j.neuron.2023.02.022. Epub 2023 Mar 14.
Reference Type
BACKGROUND
Matsui M, Nakanishi T, Noguchi T, Ferrone S. Synergistic in vitro and in vivo anti-tumor effect of daunomycin-anti-96-kDa melanoma-associated antigen monoclonal antibody CL 207 conjugate and recombinant IFN-gamma. J Immunol. 1988 Aug 15;141(4):1410-7.
Reference Type
BACKGROUND
Thakkar M, Edelenbos J, Dore S. Bilirubin and Ischemic Stroke: Rendering the Current Paradigm to Better Understand the Protective Effects of Bilirubin. Mol Neurobiol. 2019 Aug;56(8):5483-5496. doi: 10.1007/s12035-018-1440-y. Epub 2019 Jan 5.
Reference Type
BACKGROUND
Vitek L, Tiribelli C. Bilirubin: The yellow hormone? J Hepatol. 2021 Dec;75(6):1485-1490. doi: 10.1016/j.jhep.2021.06.010. Epub 2021 Jun 18.
Reference Type
BACKGROUND
Zhong XM, Ren XC, Lou YL, Chen MJ, Li GZ, Gong XY, Huang Z. Effects of in-vitro cultured calculus bovis on learning and memory impairments of hyperlipemia vascular dementia rats. J Ethnopharmacol. 2016 Nov 4;192:390-397. doi: 10.1016/j.jep.2016.09.014. Epub 2016 Sep 9.
Reference Type
BACKGROUND
Lu F, Wang L, Chen Y, Zhong X, Huang Z. In vitro cultured calculus bovis attenuates cerebral ischaemia-reperfusion injury by inhibiting neuronal apoptosis and protecting mitochondrial function in rats. J Ethnopharmacol. 2020 Dec 5;263:113168. doi: 10.1016/j.jep.2020.113168. Epub 2020 Jul 27.
Reference Type
BACKGROUND
Takahashi K, Azuma Y, Shimada K, Saito T, Kawase M, Schaffer SW. Quality and safety issues related to traditional animal medicine: role of taurine. J Biomed Sci. 2010 Aug 24;17 Suppl 1(Suppl 1):S44. doi: 10.1186/1423-0127-17-S1-S44.
Reference Type
BACKGROUND
Tang Y, Han Z, Zhang H, Che L, Liao G, Peng J, Lin Y, Wang Y. Characterization of Calculus bovis by principal component analysis assisted qHNMR profiling to distinguish nefarious frauds. J Pharm Biomed Anal. 2023 May 10;228:115320. doi: 10.1016/j.jpba.2023.115320. Epub 2023 Mar 1.
Reference Type
BACKGROUND
Liu Y, Tan P, Liu S, Shi H, Feng X, Ma Q. A new method for identification of natural, artificial and in vitro cultured Calculus bovis using high-performance liquid chromatography-mass spectrometry. Pharmacogn Mag. 2015 Apr-Jun;11(42):304-10. doi: 10.4103/0973-1296.153083.
Reference Type
BACKGROUND
Li X, Yao Y, Chen M, Ding H, Liang C, Lv L, Zhao H, Zhou G, Luo Z, Li Y, Zhang H. Comprehensive evaluation integrating omics strategy and machine learning algorithms for consistency of calculus bovis from different sources. Talanta. 2022 Jan 15;237:122873. doi: 10.1016/j.talanta.2021.122873. Epub 2021 Sep 30.
Reference Type
BACKGROUND
Shimada K, Azuma Y, Kawase M, Takahashi T, Schaffer SW, Takahashi K. Taurine as a marker for the identification of natural Calculus Bovis and its substitutes. Adv Exp Med Biol. 2013;776:141-9. doi: 10.1007/978-1-4614-6093-0_15.
Reference Type
BACKGROUND
Shi Y, Xiong J, Sun D, Liu W, Wei F, Ma S, Lin R. Simultaneous quantification of the major bile acids in artificial Calculus bovis by high-performance liquid chromatography with precolumn derivatization and its application in quality control. J Sep Sci. 2015 Aug;38(16):2753-62. doi: 10.1002/jssc.201500139. Epub 2015 Jun 30.
Reference Type
BACKGROUND
Yu ZJ, Xu Y, Peng W, Liu YJ, Zhang JM, Li JS, Sun T, Wang P. Calculus bovis: A review of the traditional usages, origin, chemistry, pharmacological activities and toxicology. J Ethnopharmacol. 2020 May 23;254:112649. doi: 10.1016/j.jep.2020.112649. Epub 2020 Feb 14.
Reference Type
BACKGROUND
Zhou J, Jiang T, Wang J, Wu W, Duan X, Jiang H, Jiao Z, Wang X. Multimodal investigation reveals the neuroprotective mechanism of Angong Niuhuang pill for intracerebral hemorrhage: Converging bioinformatics, network pharmacology, and experimental validation. J Ethnopharmacol. 2024 Jan 30;319(Pt 1):117045. doi: 10.1016/j.jep.2023.117045. Epub 2023 Aug 24.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBSinICH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction
NCT02544087
UNKNOWN
NA
Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
NCT03354026
UNKNOWN
PHASE4
Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
NCT01918722
UNKNOWN
PHASE4
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06673602
RECRUITING
PHASE4
China Stroke Registry for Patients With Traditional Chinese Medicine
NCT04921397
UNKNOWN
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy
NCT07250035
NOT_YET_RECRUITING
PHASE3
A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis
NCT01553643
UNKNOWN
PHASE4
A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
NCT03725865
UNKNOWN
EARLY_PHASE1
Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage
NCT04857632
RECRUITING
PHASE2/PHASE3
Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke
NCT00966316
COMPLETED
PHASE4
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
NCT03296618
UNKNOWN
PHASE1
Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke
NCT01428401
COMPLETED
PHASE2
Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial
NCT05066620
UNKNOWN
PHASE3
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
NCT04415164
UNKNOWN
PHASE4
Efficacy and Safety of Angong Niuhuang Wan for Stroke
NCT04236427
UNKNOWN
PHASE2/PHASE3
Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS
NCT06883110
RECRUITING
NA
Efficacy and Safety of Qi Zhi Tong Luo Capsule in Vascular Cognitive Impairment
NCT04301466
COMPLETED
PHASE2/PHASE3
Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients
NCT06549582
NOT_YET_RECRUITING
NA
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
NCT03358901
UNKNOWN
PHASE1
Study of the Pathogenesis and Molecular Mechanism of "YURE" in Internal Intractable Diseases
NCT00569088
UNKNOWN
PHASE2
The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools
NCT06342206
RECRUITING
Perioperative Neuroprotection of Stellate Ganglion Block
NCT02275247
UNKNOWN
NA
Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
NCT02975076
UNKNOWN
NA
AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine
NCT00351806
COMPLETED
PHASE4
Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke
NCT01336153
COMPLETED
PHASE4